CNR1 genotype influences HDL-cholesterol response to change in dietary fat intake
Heidi J Silver1, Kevin D Niswender, Charles D Keil
1Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America. heidi.j.silver@vanderbilt.edu
Insights
A specific gene variation (CNR1 H3 haplotype) influences how women's HDL-cholesterol levels respond to dietary fat changes, potentially impacting cardiovascular disease risk.
Area of Science:
- Genetics
- Cardiovascular Disease Research
- Nutritional Science
Background:
- Cardiovascular disease (CVD) burden is exacerbated by obesity-related dyslipidemia.
- HDL-cholesterol (HDL-C) is inversely correlated with CVD risk.
- A common CNR1 haplotype (H3) was previously found to protect against HDL-C reduction during weight gain.
Purpose of the Study:
- To investigate the effect of CNR1 haplotype on HDL-C response to dietary fat modifications.
- To examine these effects in both weight maintenance and weight loss contexts.
Main Methods:
- Genotyped six haplotype tagging SNPs in the CNR1 gene locus in 590 adults.
- Modified dietary fat intake (high vs. low fat conditions).
- Compared lipid profiles between carriers and non-carriers of common CNR1 haplotypes (H1-H5).
Main Results:
- In normal to overweight females on eucaloric diets, the H3 haplotype was linked to higher HDL-C levels after a high-fat diet (5.9 mg/dl difference, p=0.007).
- In obese females on a calorie-restricted high-fat diet for 16 weeks, H3 carriers also showed significantly higher HDL-C levels (6.8 mg/dl difference, p=0.009).
Conclusions:
- Variability in the CNR1 gene locus contributes to gender-specific HDL-C responses to dietary fat intake changes.
- Further in vitro studies could provide therapeutic insights for dietary interventions in obesity.
Background:
Success in further reducing the burden of cardiovascular disease (CVD) is threatened by the increasing prevalence of obesity-related atherogenic dyslipidemia. HDL-cholesterol (HDL-C) level is inversely correlated with CVD risk; each 1 mg/dl decrease in HDL-C is associated with a 6% reduction in risk. We previously showed that a common CNR1 haplotype, H3 (frequency 20%), is protective against the reduction in HDL-C that typically accompanies weight gain. In the present study, we extend that observation by reporting the effect of CNR1 haplotype on HDL-C response to modification of dietary fat intake in weight maintenance and weight loss.
Methods:
Six haplotype tagging SNPs that cover the CNR1 gene locus were genotyped in 590 adults of varying body mass index (cohort 1 is 411 males with BMI 18.5-30.0 kg/m(2); cohort 2 is 71 females with BMI18.5-30.0 kg/m(2); and cohort 3 is 108 females with BMI 30-39.9 kg/m(2)). Dietary intakes were modified so that fat intake in the "high fat" condition was 15-20% greater than in the "low fat" condition, and lipid profiles were compared between carriers versus noncarriers for each of the five commonly observed CNR1 haplotypes (H1-H5).
Results:
In normal to overweight subjects on eucaloric diets, the H3 haplotype was significantly associated with short-term high fat diet induced changes in HDL-C level in females (carriers 5.9 mg/dl>noncarriers, p = 0.007). The H3 haplotype was also significantly associated with HDL-C level after 16 weeks on high fat calorie restricted diet in obese females (carriers 6.8 mg/dl>noncarriers, p = 0.009).
Conclusion:
Variability within the CNR1 gene locus contributes to gender-related differences in the HDL-cholesterol response to change in dietary fat intake. Functional characterization of this relationship in vitro may offer insights that potentially yield therapeutic guidance targeting dietary macronutrient composition, a direction much needed in the current epidemic of obesity.
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipid Catabolism
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

